SANOFI-AVENTIS has launched
a hostile bid for Genzyme, after
management at the target
company refused to negotiate.
The US$69 per share offer is at
the same price already rebuffed by
Genzyme a month ago, but is now
being offered directly to Genzyme
shareholders.
Sanofi-aventis ceo Chris
Viehbacher said “we believe the
offer will be successful ultimately.
“Sanofi-aventis has a history of
being a patient, disciplined buyer.”The above article was sent to subscribers in Pharmacy Daily's issue from 05 Oct 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Oct 10
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.